Technosphere Insulin

Phase 2

MMannkind Corporation

Technosphere Insulin is one of 43 therapeutic programs targeting Type 1 Diabetes Mellitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Type 1 Diabetes MellitusRecruiting

Type 1 Diabetes MellitusPhase 2

Recruiting

Competition

Competitive Landscape

249 competitors in Type 1 Diabetes Mellitus

#DrugCompanyPhaseTrials

Victoza

Novo Nordisk

Phase 3

4 2

Symlin

AstraZeneca

Phase 3

3 3

Tecfidera

Biogen

Phase 3

1 4

Galvus

Novartis

Phase 3

1 5

Suglat

Astellas

Phase 3

1 6

Zinbryta

Simulect

Zegalogue

1 9

LY2605541

Eli Lilly

Phase 3

2 10

Inhaled Insulin

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Type 1 Diabetes Mellitus

NCT07224321

Clinical

Trials by Indication[1]

Type 1 Diabetes Mellitus1 trial

INHALE-1st: Technosphere Insulin (Afrezza®) In Combination With Basal Insulin For Youth With Newly-Diagnosed Type 1 Diabetes

Recruiting·MMannkind Corporation·Phase 2·NCT07224321·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Technosphere Insulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Technosphere Insulin. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Mannkind Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: MMannkind Corporation

Technosphere Insulin

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Type 1 Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News